Tags : AS

Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment

Vartika Singh November 1, 2018

Shots: The approval is based on the non-inferiority data demonstrating its biosimilarity in terms of PK, immunogenicity and safety meeting all 1Eps & results of ADACCESS study confirming its safety […]readmore

Biotech

Novartis Receives EU Approval for Cosentyx’s (secukinumab) Label Update in

Vartika Singh October 26, 2018

Shots: The label update includes dosing flexibility of Cosentyx up to 300 mg based on clinical response & SC structural data of 24 wks., showing inhibition in progression of joint […]readmore

Tags : AS

Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment

Novartis Receives EU Approval for Cosentyx’s (secukinumab) Label Update in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : AS

Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment

Novartis Receives EU Approval for Cosentyx’s (secukinumab) Label Update in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company